Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324
Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic
Solution, 0.5%